Running Point Capital Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Running Point Capital Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$12K	–	239
2022 Q3	$12K	Hold	10,000	–	–	0.01%	196
2022 Q2	$18K	Hold	10,000	–	–	0.01%	190
2022 Q1	$20K	Buy	+10,000	New	+$19.6K	0.01%	189

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT)

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Running Point Capital Advisors's CLVS Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 10,000 shares — an estimated $12K sold.

Running Point Capital Advisors first reported a position in CLVS in Q1 2022 and held it in 3 quarters. The position peaked at $20K in Q1 2022. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Running Point Capital Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Running Point Capital Advisors sold 10,000 Clovis Oncology, Inc. shares in Q4 2022, an estimated $12K.
Running Point Capital Advisors first reported a position in Clovis Oncology, Inc. in Q1 2022 and held it in 3 quarters.
Running Point Capital Advisors's Clovis Oncology, Inc. position peaked at $20K in Q1 2022.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.